Swiss pharmaceutical company Sandoz is launching a generic semaglutide, the main ingredient of Ozempic, in the U.S. when the market opens in 2030, Bloomberg reported Sept. 3.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
